Immunophenotyping parameters as prognostic factors in T-acute leukemia patients

Neoplasma

Volumn 56, Issue 6, 2009, Pages 508-513

  Babusikova, O ^a   Stevulova, L ^a   Fajtova, M ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Multiparameter flow cytometry; Prognostic factors of follow up of T ALL patients; T acute lymphoblastic leukemia; T cell differentiation antigens; T cell maturation sequence

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; T6 ANTIGEN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CELL MATURATION; CHILD; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMATOPOIETIC CELL; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRESCHOOL CHILD; PROGNOSIS; SCHOOL CHILD; T CELL LEUKEMIA; T LYMPHOCYTE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PHENOTYPE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70449715857     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_06_508     Document Type: Article

References (26)

1. PUI Ch, EVANS WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-78. doi:10.1056/NEJMra052603
2. DE LEVAL L, BISIG B, THIELEN C et al. Molecular classification of T-cell lymphomas. Crit Rev Oncol/Hematol 2009; doi:10.1016/j.critrevonc.2009.01.002 doi:10.1016/j.critrevonc.2009.01.002
3. GOLDBERG JM SILVERMAN LB, JEVY DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21 (19): 3616-22. doi:10.1200/JCO.2003.10.116
4. BÉNÉ MC, CASTOLDI G, KNAPP W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-6.
5. CHARETTI S, FOÀ R. T-cell acute lymphoblastic leukemia. Haematologica 2009; 94 (2): 160-2. doi:10.3324/haematol.2008.004150
6. FISCHER L, GÖKBUGET N, SCHWARTZ S, et al. CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica 2009; 94: 224-9. doi:10.3324/haematol.13543
7. CHIARETTI S, GENTLEMAN R, CAMPANA D, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 2004; 103: 2771-8. doi:10.1182/blood-2003-09-3243
8. COUSTAN-SMITH E, MULLIGHAN CG, ONCIU M et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-56. doi:10.1016/S1470-2045(08)70314-0
9. DALMAZZO LF, JÁCOMO RH, MARINATO AF, et al. The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. Br J Haematol. 2009; 144 (2): 223-9. doi:10.1111/j.1365-2141.2008.07457.x
10. DEMAREST RM, RATTI F, CAPOBIANCO AJ. It's T-ALL about Notch. Oncogene 2008; 27: 5082-91.
11. FERRANDO AA, ARMSTRONG SA, NEUBERG DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003; 102: 262-8. doi:10.1182/blood-2002-10-3221
12. SPELEMAN F, CAUWELIER B, DASTUGUE N, et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 2005; 19: 358-66. doi:10.1038/sj.leu.2403657
13. DIK WA, BRAHIM W, BRAUN C, et al. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia 2005; 19: 1948-57. doi:10.1038/sj.leu.2403891
14. BABUŠÍKOVÁ O, ŽELEZNÍKOVÁ T, KIRSCHNEROVÁ G, et al.: Hematogones in acute leukemia during and after therapy. Leukemia & Lymphoma, 2008 Oct; 49 (10): 1935-1944. doi:10.1080/10428190701817274
15. BÉNÉ MC: Immunophenotyping of acute leukaemias. Immunology Letters 98; 2005: 9-21 doi:10.1016/j.imlet.2004.10.008
16. SHUSTER JJ, FALLETTA JM, PULLEN DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75: 166-73.
17. UCKUN FM, GAYNON PS, SENSEL MG, et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 1997; 15: 2214-21.
18. SCHRAUDER A, REITER A, GADNER H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 2006; 24: 5742-49. doi:10.1200/JCO.2006.06.2679
19. CAMPANA D.: Determination of minimal residual disease in leukaemia patients. Br J Haematol, 2003; 121(6):823-838. doi:10.1046/j.1365-2141.2003. 04393.x (Pubitemid 36760300)
20. ZIPF T.F., JOHNSTON D.A.: Leukemia and lymphoma: detection of minimal residual disease. New Jersey, Humana Press, 2003:119-162.
21. ROTHENBERG EV, MOORE JE, YUI MA. Launching the T-cell-lineage developmental programme. Nat Rev Immunol 2008; 8: 9-21. doi:10.1038/nri2232
22. BELL JJ, BHANDOOLA A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008; 452: 764-67. doi:10.1038/nature06840
23. WADA H, MASUDA K, SATOH R, et al. Adult T-cell progenitors retain myeloid potential. Nature 2008; 452: 768-72. doi:10.1038/nature06839
24. BALCIUNAITE G, CEREDIG R, ROLINK AG. The earliest subpopulation of mouse thymocytes contains potent T, significant macrophage, and natural killer cell but no B-lymphocyte potential. Blood 2005; 105: 1930-36. doi:10.1182/blood-2004- 08-3087
25. SOULIER J, CLAPPIER E, CAVUELA JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005; 106 (1): 274-276. doi:10.1182/blood-2004-10-3900
26. WOUTERS BJ, JORDA MA, KEESHAN K, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007; 110: 3706-14. doi:10.1182/blood-2007-02-073486